8 Advancing a Robust, Differentiated Cell Therapy Pipeline This presentation is for investor relations purposes only - Not for product promotional purposes Notes： 1. In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. NDMM = Newly Diagnosed Multiple Myeloma. 2. Phase 1 investigator-initiated trial in China 3. IND applications have been cleared by the United States FDA 4. Subject to an exclusive license agreement with Novartis Pharma AG. The safety and efficacy of the agents and/or uses under investigation have not been established. There is no assurance that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. Additionally, as some programs are still confidential, certain candidates may not be included in this list PartnerCurrent StatusNDAPhase IIIPhase IIPhase IPre-ClinicalIndicationTargetProgram CARVYKTI®: BCMA-directed Autologous Therapy Patient follow-upNDMM (Front-line) (Transplant Not Intended) (CARTITUDE-5)(1) BCMACARVYKTI® Patient follow-upNDMM (Front-line, Transplant Eligible) (CARTITUDE-6)(1) EnrollingNDMM (Front-line, Transplant Not Intended) (CARTITUDE-10)(1) Autologous Therapies Met primary endpoint, patient follow-upRelapsed/Refractory Gastric & Pancreatic Cancers(3)Claudin 18.2LB1908 Met primary endpoint, patient follow-up2L+ Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma (3)(4)DLL3LB2102 Patient follow-upRelapsed/Refractory Multiple Myeloma(2)GPRC5DLB2401 Patient follow-upRelapsed/Refractory Multiple Myeloma(2)CD19 x GPRC5DLB2402 Patient follow-upRelapsed/Refractory Multiple Myeloma(2)GPRC5D (FAST CAR)LB2403 EnrollingRelapsed/Refractory Multiple Myeloma(2)FcRH5 (FAST CAR)LB2502 Allogeneic Therapies EnrollingRelapsed/Refractory Autoimmune Diseases(2)CD19 x CD70 (CAR-γδ T)LB2404D EnrollingRelapsed/Refractory Autoimmune Diseases(2)CD19 x BCMA (CAR-NK)LB2405 EnrollingRelapsed/Refractory B-cell Non-Hodgkin Lymphoma(2)CD20 (CAR-αβ T)LB2302 EnrollingRelapsed/Refractory B-cell Non-Hodgkin Lymphoma(2)CD19 x CD20 (CAR-γδ T)LB2303 EnrollingRelapsed/Refractory B-cell Non-Hodgkin Lymphoma(2)CD19 x CD20 (CAR-γδ T)LB2406 In Vivo Therapies EnrollingRelapsed/Refractory B-cell Non-Hodgkin Lymphoma(2)CD19 x CD20LB2501 EnrollingRelapsed/Refractory Multiple Myeloma(2)GPRC5DLB2503 InitiatingRelapsed/Refractory Autoimmune Diseases(2)BCMALB2505 Multi-Regional Clinical Trial Multi-Regional Clinical Trial US IND US IND Multi-Region Single Arm Trial